A number of other equities analysts have also weighed in on MDG1. Oddo Bhf set a €13.00 ($16.05) price target on shares of MediGene and gave the stock a neutral rating in a research report on Friday, March 23rd. Independent Research set a €16.50 ($20.37) target price on shares of MediGene and gave the company a neutral rating in a report on Thursday, March 22nd.
MDG1 opened at €13.70 ($16.91) on Wednesday. MediGene has a twelve month low of €8.53 ($10.53) and a twelve month high of €19.27 ($23.79).
MediGene Company Profile
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.